The first sublicensing agreements for Shionogi & Co. Ltd.’s Xocova (ensitrelvir; S-217622) have been reached following the Japanese firm's alliance with the Medicines Patent Pool (MPP) last year. Deals have now been signed for the oral COVID-19 antiviral with seven generic firms in China, India, Ukraine and Vietnam.
If they successfully proceed, the arrangement means that officially licensed generic versions can be launched earlier than usual after the...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
